RxDoctor Payments DataLook up a doctor →

Matthew Lockwood, MD

Hematology & Oncology · Fayetteville, ARNPI 1265875470

Payments from drug & device makers

$209,963in general payments, 2019–2025

Across 415 payments — averaging $505.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$188K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Daiichi Sankyo Inc.$783
  • Johnson & Johnson$765
  • Bristol Myers Squibb$458
  • Merck$382
  • plus $4K from 54 others
$31,749in research payments, 2019–2025

Across 1 payment — averaging $31,749 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$32K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly7$188,072
E.r. Squibb & Sons, L.L.C.3$15,319
Daiichi Sankyo Inc.13$783
Johnson & Johnson(2 entities)40$765
Bristol Myers Squibb41$458
Merck28$382
AstraZeneca23$348
Novartis21$336
Sanofi19$273
AVEO Pharmaceuticals, Inc.18$265
Eisai Inc.17$252
Beigene USA, Inc.10$247
Amgen19$222
Astellas Pharma US Inc13$187
Ipsen Biopharmaceuticals, Inc11$164
Exelixis Inc.11$137
Takeda Pharmaceuticals U.S.A., Inc.8$114
Bayer8$113
GSK8$112
Regeneron Healthcare Solutions, Inc.6$93
Gilead(2 entities)6$75
Jazz Pharmaceuticals Inc.5$71
Pfizer5$67
EMD Serono, Inc.5$64
Lilly USA, LLC4$59
Taiho Oncology, Inc.4$58
Genmab U.S., Inc.3$52
Kyowa Kirin, Inc.4$52
Iovance Biotherapeutics, Inc.3$49
Puma Biotechnology, Inc.3$48
Sumitomo Pharma America, Inc.2$46
Karyopharm Therapeutics Inc.3$45
Sobi, Inc3$43
Alnylam Pharmaceuticals Inc.3$40
Rigel Pharmaceuticals, Inc.3$35
Seagen Inc.3$35
Dendreon Pharmaceuticals LLC2$30
Fennec Pharmaceuticals, Inc.1$28
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$27
Genentech USA, Inc.1$27
Agios Pharmaceuticals, Inc.1$25
Boehringer Ingelheim2$25
Pharmacyclics LLC, An Abbvie Company2$24
Heron Therapeutics, Inc.2$24
Myovant Sciences Inc.1$22
Clovis Oncology, Inc.2$20
Recordati_rare_diseases_inc.1$19
Sanofi-aventis U.S. LLC1$18
AbbVie1$16
Progenics Pharmaceuticals, Inc.1$15
Telix Pharmaceuticals1$15
Morphosys, US Inc.1$14
Pharmaessentia USA Corporation1$13
Springworks Therapeutics, Inc.1$13
Servier Pharmaceuticals LLC1$13
Verity Pharmaceuticals Inc.1$13
Blueprint Medicines Corporation1$13
Blue Earth Diagnostics1$13
AMAG Pharmaceuticals, Inc.1$12
Epizyme, Inc.1$12

How this compares

$209,963 in reported general payments places this provider in the 80th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$8,287,363
Medicare patients
1,547
Services billed
331,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fayetteville

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →